Treatment enquiry? Call free on: 0808 1569 565
Are you a doctor? Refer a Patient
Are you a patient? Make an Enquiry

Strategic partnership helps achieve a better result for cancer patients in the UK and around the World.

Strategic partnership helps achieve a better result for cancer patients in the UK and around the world


Radiotherapy machine Versa HD LINAC

GenesisCare have formed an eight year strategic partnership with Elekta, a pioneering provider of sophisticated, systems and software for cancer patients. This partnership ensures GenesisCare patients in the UK and around the world will have access to the most advanced and recognised cancer treatment solutions available.

Australia’s largest cancer and cardiac services organisation, GenesisCare, has today announced the formation of a multi-year strategic partnership with Swedish medical equipment manufacturer, Elekta AB.
The partnership, initially over eight years, will include order bookings valued at more than AUD$132 million (USD$100 million).

GenesisCare Managing Director, Dan Collins, said: “Our ambition is to transform health care and improve outcomes for cancer patients around the world by improving access to high quality care. This is facilitated by the coordination of enterprise-wide practices and enhanced cancer management technology available for use by our committed and highly skilled medical teams.

“The suite of technology solutions, global reach and commitment to innovation offered by Elekta helps us to achieve a better result for patients.”

The partnership includes the acquisition of solutions across Elekta’s portfolio, including Leksell Gamma Knife® Icon™ radiosurgery systems, Versa HD™ linear accelerators, brachytherapy systems, software as well as services. These products and solutions will be acquired by GenesisCare cancer treatment centres in Australia, the UK and new international markets.

GenesisCare is also expected to order Elekta’s high-field (1.5 Tesla) MRI-guided linear accelerator (MR-linac*) when this new treatment technology is available in the market in 2017.

“The MR-linac is a game changer. We expect it will improve the accuracy of treatment and provide a smoother patient experience which should improve outcomes. We expect cancer patients, including those receiving treatment for prostate, breast and other cancers, to benefit from this innovation,” said Mr Collins.

Of the partnership, Tomas Puusepp, President and CEO of Elekta said: “We are proud to partner alongside GenesisCare and support their exciting vision. GenesisCare will receive the most advanced and recognised cancer treatment solutions on the market. Both Leksell Gamma Knife and Versa HD are known for their extreme accuracy, efficiency and outstanding outcomes. We are looking forward to being GenesisCare’s partner as they expand into new markets.”

Software systems included in the agreement comprise Elekta’s MOSAIQ® enterprise licensing, which provides a full-featured OIS to enable a completely optimized, automated workflow across their entire global enterprise – to fulfill the organization’s “Cancer Services of the Future” vision. The deal also includes METRIQ®, a fully integrated cancer registry for data collection and follow-up through reporting and analysis.

*Elekta’s MR-linac is a works in progress and not yet available for sale or distribution in Australia or the UK.

-- ENDS --

Make an enquiry

Contact us using our online form, and we'll do what we can to help.

Press enquires

For all press and media relations enquires, please click on the link below.


Find a consultant

Specialist Cancer Consultant

We work with some of the UK's leading consultant surgeons, oncologists, and radiologists - find one with the expertise you need.


Deep Inspiration Breath-hold Brochure

Download the GenesisCare deep inspiration breath-hold brochure.


On 8th January 2016, we changed our name to GenesisCare.